3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Inflammation
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
KRAS Mutant Non-Small Cell Lung Cancer
1
Immune System Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
Surveys and Questionnaires
5
Nivolumab
5
pembrolizumab
3
atezolizumab
3
Radiosurgery
3
pralsetinib
2
pertuzumab
2
cobimetinib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Exercise
2
Drug Therapy
2
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
talazoparib
1
selpercatinib
1
repotrectinib
1
remune
1
ponatinib
1
pemigatinib
1
pazopanib
1
palbociclib
1
osimertinib
1
motexafin gadolinium
1
montanide ISA 51
1
itacitinib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
palbociclib
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled